论文部分内容阅读
目的探讨强化清髓不含胸腺细胞免疫球蛋白的单份非血缘脐血移植治疗伴中枢神经系统白血病(central nervous system leukemia,CNSL)的急性白血病疗效。方法回顾性分析2009年7月至2014年9月在我科接受该治疗的15例急性白血病患者临床特征,其中急性单核细胞白血病2例,急性未分化型白血病1例,急性淋巴细胞白血病12例。所有患者既往化疗过程中存在CNSL,经治疗后移植前CNSL均达完全缓解。全部采用强化清髓预处理方案,其中全身照射/Ara-C/CY方案9例,Ara-c/Bu/CY方案3例,Flu/Bu/CY方案3例,预防移植物抗宿主病(graft-versus-host disease,GVHD)方案为环孢素联合短程霉酚酸酯。结果 14/15例(93.3%)患者获得造血重建,中性粒细胞、血小板植入的中位时间分别为19(13~27)d和41(20~85)d。移植相关并发症:80%(12/15)患者出现植入前综合征;14例可评估的患者中,3例患者出现Ⅱ~Ⅳ度急性GVHD,累积发生率为20.00%,1例患者出现Ⅲ~Ⅳ度急性GVHD,累积发生率为13.33%;3例患者出现局限型皮肤慢性GVHD,移植后720 d累积发生率为20.00%,无广泛型慢性GVHD的发生。所有患者中位随访时间43.2(14.1~76.5)个月,因植入前多脏器功能衰竭死亡1例,重度急性GVHD死亡1例及原发病复发死亡2例;复发3例,其中2例骨髓复发,仅1例CNSL复发,经鞘内注射及头颅放疗,脑脊液恢复正常。3年预计总生存率及无白血病生存率分别为60.0%和53.3%。结论强化清髓不含胸腺细胞免疫球蛋白的单份非血缘脐血移植治疗伴CNSL的急性白血病初步结果显示疗效较好,值得推广应用。
Objective To investigate the curative effect of intensive myeloablation of single non-blood cord blood transplantation without thymocyte immunoglobulin in the treatment of acute leukemia with central nervous system leukemia (CNSL). Methods The clinical features of 15 patients with acute leukemia receiving this treatment from July 2009 to September 2014 were analyzed retrospectively. Among them, 2 were acute monocytic leukemia, 1 were acute undifferentiated leukemia, 1 were acute lymphoblastic leukemia example. All patients had CNSL in the course of previous chemotherapy and achieved complete remission of CNSL after transplantation. All of them were treated with intensive myelo-preconditioning. Among them, 9 were Ara-C / CY, 3 were Ara-c / Bu / CY and 3 were Flu / Bu / -versus-host disease, GVHD) regimen is cyclosporine in combination with short-acting mycophenolate mofetil. Results The median time for hematopoietic reconstitution, neutrophil and platelet transplantation in 14/15 patients (93.3%) was 19 (13-27) d and 41 (20-85) d, respectively. Implantation-related complications: Preimplantation syndrome occurred in 80% (12/15) of patients; acute GVHD in grade II-IV occurred in 3 of 14 evaluable patients, with a cumulative incidence of 20.00%, and 1 patient developed Ⅲ ~ Ⅳ acute GVHD, the cumulative incidence was 13.33%. Three patients had localized chronic GVHD. The cumulative incidence at 720 days after transplantation was 20.00%, with no extensive chronic GVHD. The median follow-up time was 43.2 (14.1-76.5) months in all patients, 1 patient died of multiple organ failure before transplantation, 1 patient died of severe acute GVHD and 2 patients died of recurrent disease. Three patients were recurred, of which 2 patients Bone marrow recurrence, only 1 case of CNSL recurrence, intrathecal injection and cranial radiotherapy, cerebrospinal fluid returned to normal. 3-year estimated total and non-leukemia survival rates were 60.0% and 53.3%. CONCLUSION: The preliminary results of the treatment of acute leukemia with CNSL by single myotonic cord blood transplantation without thymocyte immunoglobulin with enhanced myeloablation show a good curative effect and should be popularized and applied.